| 18.44 -0.35 (-1.86%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.24  |
1-year : | 26.27 |
| Resists | First : | 20.76 |
Second : | 22.5 |
| Pivot price | 19.91 |
|||
| Supports | First : | 17.95 |
Second : | 14.93 |
| MAs | MA(5) : | 19.08 |
MA(20) : | 20.22 |
| MA(100) : | 21.74  |
MA(250) : | 17.07 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 16.5 |
D(3) : | 23.2 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 30 | Low : | 3.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ URGN ] has closed above bottom band by 12.3%. Bollinger Bands are 24.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.21 - 19.4 | 19.4 - 19.51 |
| Low: | 17.57 - 17.8 | 17.8 - 17.95 |
| Close: | 18.17 - 18.55 | 18.55 - 18.79 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Fri, 13 Mar 2026
Bladder cancer survey: 80% of patients live with fear it will return - Stock Titan
Mon, 09 Mar 2026
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Thu, 05 Mar 2026
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
Tue, 03 Mar 2026
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Tue, 03 Mar 2026
UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives - Sahm
Mon, 02 Mar 2026
Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026 - Meyka
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 97.8 (%) |
| Shares Short | 9,340 (K) |
| Shares Short P.Month | 10,570 (K) |
| EPS | -3.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.19 |
| Profit Margin | -139.9 % |
| Operating Margin | -50.6 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 54 % |
| Gross Profit (p.s.) | 2.07 |
| Sales Per Share | 2.34 |
| EBITDA (p.s.) | -2.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -162 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -5.32 |
| PEG Ratio | 0 |
| Price to Book value | -8.46 |
| Price to Sales | 7.86 |
| Price to Cash Flow | -5.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|